Ignite Creation Date:
2025-12-24 @ 1:37 PM
Ignite Modification Date:
2025-12-31 @ 3:40 AM
Study NCT ID:
NCT05631795
Status:
COMPLETED
Last Update Posted:
2025-12-03
First Post:
2022-11-21
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-08-09
Start Date Type:
ACTUAL
Primary Completion Date:
2025-06-12
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-06-12
Completion Date Type:
ACTUAL
First Submit Date:
2022-11-21
First Submit QC Date:
None
Study First Post Date:
2022-11-30
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-02
Last Update Post Date:
2025-12-03
Last Update Post Date Type:
ESTIMATED